secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2025-10-20T23:59:59+00:00
Accession:  0001104659-25-100537
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem partner reports 41% ORR for VS-7375 in heavily pre-treated KRAS G12D PDAC at ESMO 2025
--------------------------------------------------------------------------------

- ORR of 41% (24/59) in heavily pre-treated advanced KRAS G12D PDAC at 600 mg daily; DCR 96.7%.
- Month-four OS rate 92.2%, median OS not reached; median PFS 5.52 months, 4-month PFS rate 78.2%.
- 91.5% of patients had tumor reduction; 47% still on treatment; longest treatment >1 year.
- Safety: 30.3% Grade 3 TRAEs, 3% discontinuation due to TRAEs, no TRAE-related deaths; mean dose intensity 93%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925100537/0001104659-25-100537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925100537/tm2529024d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-100537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer